Al-Ola A Abdallah: What is the Deal of mRNA Vaccine Against Cancer from Russia?
Al-Ola A Abdallah, Director of Plasma Cell Disorder Program at the University of Kansas Medical Center, shared a post on X:
“What is the deal of mRNA vaccine against cancer from Russia:
An mRNA vaccine against cancer is entering human trials in late 2025. It’s personalized, AI-driven, and 100% free for Russian citizens. Here’s what you need to know.
What is it?
A custom-built mRNA cancer vaccine – designed individually for each patient. It uses tumor-specific neoantigens to train the immune system to attack cancer cells.
How it works:
– AI analyzes a patient’s tumor
- A unique mRNA vaccine is created
- Manufacturing takes ~1 week
- Injected to trigger an immune response against the tumor
First target: Melanoma
The vaccine will first be tested on melanoma patients, with plans to expand to:
• Pancreatic cancer
• Kidney cancer
• Lung cancer
Cost?
Each dose: ~₽300,000 (≈$2,870 USD)
But Russian citizens will get it free under public healthcare!
What do we know so far?
Animal studies show reduced tumor growth and metastasis.
First human trials begin Sept-Oct 2025 at major cancer centers in Moscow.
Regulation
Russia has created a special approval path for personalized mRNA therapies—separate from traditional drug approvals. A bold regulatory move.
The Catch?
As exciting as it sounds, we still need to see peer-reviewed human trial results. Until then, optimism must be balanced with scientific rigor
Why it matters
This puts Russia in the global race for personalized cancer immunotherapy, alongside efforts from BioNTech, Moderna, and others.”
More posts featuring Al-Ola A Abdallah on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023